HIV medication has traveled a remarkable distance from the complicated, high-pill-count regimens of the past. Today, many people treat HIV with one tablet a day, while certain eligible patients can use long-acting injections instead. Prevention has evolved, too: PrEP is available as daily tablets, injections every two months, and a newer injection given every six months.
The names can still feel like someone spilled a bowl of alphabet soup across a pharmacy counter: ART, NRTI, INSTI, PrEP, PEP, TAF, TDF, and several others. Fortunately, the basic idea is straightforward. Different HIV medications interrupt different stages of the virus’s life cycle. Combining medicines makes it much harder for HIV to reproduce, mutate, and develop drug resistance.
This HIV medications list explains the major drug classes, commonly used combination products, prevention options, potential side effects, and practical factors that influence treatment decisions. It is an educational overviewnot a personalized prescription menu. HIV treatment should always be selected and monitored by a qualified health care professional.
What Are HIV Medications?
HIV medications are antiretroviral drugs, often abbreviated as ARVs. Treatment using these medicines is called antiretroviral therapy, or ART. ART is recommended for everyone diagnosed with HIV and should usually begin as soon as possible after diagnosis.
These medications do not remove every copy of HIV from the body. Instead, they prevent the virus from making new copies. As the viral load falls, the immune system has an opportunity to recover, CD4 cell levels may improve, and the risk of HIV-related illness drops substantially.
Most treatment regimens combine two or three active drugs from at least two medication classes. Several complete regimens package those drugs into one daily tablet, which is much friendlier than carrying a pill organizer large enough to qualify as luggage.
How HIV Medications Work
HIV must complete several steps to reproduce. It first attaches to a CD4 cell, enters the cell, converts its genetic material, inserts that material into human DNA, manufactures viral components, and assembles new virus particles. Antiretroviral drug classes block one or more of these steps.
Combination therapy matters because HIV mutates quickly. If only one weak barrier stands in its way, the virus may eventually find a detour. A properly designed regimen places several locked doors in the path at once.
The Main Goals of HIV Treatment
- Reduce the viral load to an undetectable level
- Protect and rebuild immune function
- Prevent HIV from progressing to AIDS
- Reduce the risk of opportunistic infections and certain cancers
- Prevent sexual transmission through sustained viral suppression
- Limit the development of drug-resistant HIV
Almost everyone who takes effective HIV medicine as prescribed can achieve an undetectable viral load, often within six months. A person who gets and keeps an undetectable viral load does not transmit HIV through sex. This evidence-based principle is known as U=U: Undetectable Equals Untransmittable. Undetectable does not mean cured, however, because inactive HIV remains in cellular reservoirs.
HIV Medications List by Drug Class
The following list includes commonly encountered medications and representative older drugs. It is not a recommendation to use every medicine listed. Some older products are rarely prescribed, have discontinued brand versions, or are reserved for special situations.
1. Integrase Strand Transfer Inhibitors
Integrase strand transfer inhibitors, or INSTIs, block integrase, an enzyme HIV uses to insert viral genetic material into a human cell’s DNA. Because they are effective, generally well tolerated, and relatively convenient, INSTIs form the backbone of many modern first-line regimens.
- Bictegravir available as part of Biktarvy
- Cabotegravir Vocabria; also included in Cabenuva and Apretude
- Dolutegravir Tivicay; included in Dovato, Juluca, and Triumeq
- Elvitegravir included in Genvoya and Stribild
- Raltegravir Isentress and Isentress HD
Integrase inhibitors stop HIV at a particularly important stage. A useful mental picture is a virus arriving with stolen blueprints, only to discover that the office shredder has eaten the filing instructions.
2. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
Nucleoside or nucleotide reverse transcriptase inhibitors, usually grouped as NRTIs, interfere with reverse transcriptase. HIV uses this enzyme to convert its RNA into DNA. NRTIs provide faulty building materials, causing the growing viral DNA chain to stop prematurely.
- Abacavir Ziagen
- Emtricitabine Emtriva
- Lamivudine Epivir
- Tenofovir alafenamide commonly abbreviated TAF and included in many combination tablets
- Tenofovir disoproxil fumarate Viread, commonly abbreviated TDF
- Zidovudine Retrovir; historically important but no longer commonly used for routine adult treatment
Two NRTIs are frequently paired with an integrase inhibitor. Some NRTIs, including tenofovir and emtricitabine or lamivudine, also have activity against hepatitis B, which can influence regimen selection and monitoring.
3. Non-Nucleoside Reverse Transcriptase Inhibitors
Non-nucleoside reverse transcriptase inhibitors, or NNRTIs, also target reverse transcriptase, but they do so by attaching directly to the enzyme and changing its shape.
- Doravirine Pifeltro
- Efavirenz Sustiva brand discontinued; still found in some combination or generic products
- Etravirine Intelence
- Nevirapine an older NNRTI with discontinued brand versions
- Rilpivirine Edurant; included in Complera, Odefsey, Juluca, and Cabenuva
NNRTIs can be effective components of treatment, although resistance patterns, food requirements, acid-reducing medicines, mental health history, and other drug interactions may affect which product is appropriate.
4. Protease Inhibitors
Protease inhibitors, or PIs, block HIV protease. Without this enzyme, newly produced viral material cannot be cut into the properly shaped pieces needed to create mature, infectious virus particles.
- Atazanavir Reyataz
- Darunavir Prezista
- Fosamprenavir Lexiva
- Lopinavir and ritonavir Kaletra
- Nelfinavir Viracept
- Ritonavir Norvir, usually used at a low dose as a booster
- Tipranavir Aptivus
Darunavir is one of the most commonly encountered modern PIs and has a relatively high resistance barrier. Protease inhibitors are often combined with ritonavir or cobicistat, which slow drug metabolism and increase medication levels. Boosting can be useful, but it also creates more opportunities for drug interactions.
5. CCR5 Antagonists
Maraviroc, sold as Selzentry, blocks the CCR5 receptor on certain immune cells. Some strains of HIV use this receptor as a doorway. Before maraviroc is prescribed, testing is required to confirm that the person’s virus actually uses CCR5. Installing a lock is not especially helpful when the burglar prefers a different door.
6. Fusion Inhibitors
Enfuvirtide, historically sold as Fuzeon, prevents HIV from fusing with and entering a CD4 cell. It is an injectable medication and is generally associated with specialized treatment situations rather than routine first-line care.
7. Attachment and Post-Attachment Inhibitors
- Fostemsavir Rukobia, a gp120 attachment inhibitor
- Ibalizumab-uiyk Trogarzo, an intravenous post-attachment inhibitor
These medications interfere with the early stages of viral entry and are primarily used for people with extensive treatment experience or drug-resistant HIV.
8. Capsid Inhibitors
Lenacapavir is the first approved HIV capsid inhibitor. The capsid is the protective shell surrounding HIV’s genetic material. Lenacapavir disrupts the capsid at several stages of the viral life cycle.
- Sunlenca used with other active medications to treat certain heavily treatment-experienced adults with multidrug-resistant HIV
- Yeztugo used as long-acting PrEP to prevent sexually acquired HIV
Although Sunlenca and Yeztugo contain the same active drug, they have different indications, dosing plans, and accompanying requirements. They are not interchangeable do-it-yourself projects.
Common Combination HIV Medications
Combination products place multiple antiretroviral drugs into one tablet or injection regimen. Fewer pills can make treatment easier, but the best product still depends on resistance results, kidney and liver function, hepatitis B status, pregnancy considerations, other medications, and individual preferences.
- Biktarvy bictegravir, emtricitabine, and tenofovir alafenamide
- Dovato dolutegravir and lamivudine
- Triumeq abacavir, dolutegravir, and lamivudine
- Delstrigo doravirine, lamivudine, and tenofovir DF
- Genvoya elvitegravir, cobicistat, emtricitabine, and tenofovir AF
- Odefsey emtricitabine, rilpivirine, and tenofovir AF
- Complera emtricitabine, rilpivirine, and tenofovir DF
- Symtuza darunavir, cobicistat, emtricitabine, and tenofovir AF
- Juluca dolutegravir and rilpivirine for eligible virologically suppressed patients
- Cabenuva long-acting cabotegravir and rilpivirine injections for eligible patients
Which HIV Medications Are Commonly Used First?
U.S. treatment guidelines commonly favor integrase inhibitor-based regimens for many people beginning therapy. Frequently considered approaches include bictegravir with emtricitabine and tenofovir alafenamide, or dolutegravir combined with two suitable NRTIs. Dolutegravir plus lamivudine may be appropriate for selected patients but is not suitable in every situation.
A clinician may choose another regimen when resistance, hepatitis B coinfection, pregnancy, kidney disease, cardiovascular risk, medication interactions, previous PrEP use, or insurance coverage changes the equation. The “best” HIV medication is therefore not the product with the flashiest television commercial. It is the regimen that safely suppresses that person’s virus and can be taken consistently.
Long-Acting HIV Treatment
Long-acting medicine can reduce or replace daily pills for certain patients:
- Cabenuva is generally administered every one or two months as a complete replacement regimen for eligible people whose HIV is already suppressed.
- Sunlenca is administered every six months but must be combined with an optimized background regimen for certain adults with multidrug-resistant HIV.
- Trogarzo is administered intravenously every two weeks and is used with other antiretroviral drugs.
Long-acting therapy can be liberating for someone who dislikes daily pills, needs more privacy, or struggles with a predictable medication schedule. However, injection appointments must be kept reliably. A medicine that remains in the body for months does not politely disappear when appointments are missed, so clinicians plan carefully for delays or discontinuation.
HIV Prevention Medications: PrEP
Pre-exposure prophylaxis, or PrEP, is medication used by people without HIV before a potential exposure. As of July 2026, U.S. options include two daily oral combinations and two long-acting injectable products.
Daily Oral PrEP
- Emtricitabine/tenofovir DF Truvada or a generic equivalent; approved for people with sexual or injection-related exposure risk
- Emtricitabine/tenofovir AF Descovy; approved for sexual prevention except in people whose exposure is through receptive vaginal sex
Kidney function is evaluated before oral tenofovir-based PrEP and monitored during use. People taking these medications are also tested for hepatitis B because stopping tenofovir or emtricitabine without proper follow-up can allow hepatitis B to rebound.
Injectable PrEP
- Apretude cabotegravir injection, given after initiation on an every-two-month schedule
- Yeztugo lenacapavir injection, administered every six months for eligible adults and adolescents weighing at least 77 pounds
HIV testing is essential before starting PrEP and during follow-up. Using PrEP when undiagnosed HIV is already present may expose the virus to an incomplete treatment regimen and encourage resistance.
When taken as prescribed, established oral and injectable PrEP methods are highly effective. PrEP does not prevent other sexually transmitted infections, so STI screening, condoms when appropriate, and other prevention strategies remain valuable.
Emergency HIV Prevention: PEP
Post-exposure prophylaxis, or PEP, is an emergency course of antiretroviral medication taken after a possible HIV exposure. It should be started as soon as possibleideally within 24 hours and no later than 72 hours after exposure.
The standard course lasts 28 days. Current preferred approaches for many adults and adolescents include:
- Bictegravir, emtricitabine, and tenofovir alafenamide in one tablet
- Dolutegravir plus tenofovir AF or tenofovir DF, together with emtricitabine or lamivudine
The exact regimen may be adjusted for pregnancy, age, kidney function, drug interactions, resistance concerns, and the circumstances of exposure. PEP is for emergencies, not repeated ongoing protection. Someone with continuing exposure risk may be advised to transition from PEP to PrEP.
Side Effects and Drug Interactions
Modern HIV medications are generally easier to tolerate than early antiretroviral drugs, but side effects remain possible. Common short-term effects can include nausea, diarrhea, headache, fatigue, sleep changes, or injection-site discomfort. Many improve after the first days or weeks.
Potential longer-term concerns depend on the specific medication and may involve kidney function, bone density, liver health, cholesterol, blood sugar, weight, or cardiovascular risk. Abacavir requires genetic screening for HLA-B*5701 because people with that marker have a high risk of a serious hypersensitivity reaction.
Drug interactions deserve special attention. Acid-reducing medications can interfere with certain HIV drugs. Antacids and mineral supplements may need to be separated from some integrase inhibitors. Boosted regimens can interact with cholesterol drugs, blood thinners, seizure medications, steroids, sedatives, and numerous other products.
Patients should give their clinician and pharmacist a complete list of prescriptions, over-the-counter medicines, vitamins, herbal products, and recreational substances. St. John’s wort, for example, is natural in the same sense that poison ivy is natural; “herbal” does not automatically mean harmless.
A person experiencing side effects should contact a health care professional before stopping ART. Abruptly discontinuing some drugs may allow HIV to rebound, promote resistance, or worsen hepatitis B coinfection.
How Doctors Choose an HIV Regimen
Before treatment begins, clinicians typically review viral load, CD4 count, resistance testing, hepatitis status, kidney and liver function, pregnancy considerations, and current medications. They also discuss practical questions that laboratory reports cannot answer:
- Can the patient take medication with food every day?
- Would a one-tablet regimen improve consistency?
- Are injection appointments realistic?
- Does the patient work changing shifts?
- Are cost or insurance restrictions creating barriers?
- Could privacy concerns make daily pill storage difficult?
Good HIV care treats the person rather than merely attacking a laboratory number. A technically powerful regimen that cannot be obtained, tolerated, or taken consistently is not an effective real-world plan.
Real-World Experiences With HIV Medication
The following examples are composite scenarios based on common treatment experiences rather than stories about identifiable individuals.
The First Prescription Can Feel Bigger Than the Pill
Someone newly diagnosed with HIV may receive a compact single-tablet regimen and still feel as though an entire medical warehouse has landed on the kitchen table. The prescription can represent fear, stigma, uncertainty, and the sudden expectation of lifelong treatment. Education often changes that emotional weight. Learning that modern ART can suppress HIV, protect the immune system, support a normal lifespan, and prevent sexual transmission can turn the tablet from a symbol of illness into a practical tool for control.
The first few weeks may involve mild nausea, unusual dreams, fatigue, or simply hyperawareness of every bodily sensation. A headache that would previously have been blamed on too much screen time may suddenly trigger a 2 a.m. search for “rare HIV medication complications.” Regular communication with the treatment team helps distinguish temporary adjustment effects from symptoms requiring medical attention.
Building a Routine Is Often More Important Than Willpower
Many patients discover that successful adherence is less about heroic discipline and more about designing a boring, reliable system. Medication may be paired with brushing teeth, morning coffee, feeding a pet, or a recurring phone alarm. Backup tablets might be stored safely at work or packed in carry-on luggage during travel.
People working night shifts may need a different strategy from those with regular office hours. Someone living with roommates may want discreet storage. Another person may struggle not with remembering doses, but with pharmacy delays or insurance authorization. The useful question is not, “Why can’t you just remember?” It is, “What is getting in the way, and how can the plan be redesigned?”
Reaching Undetectable Can Be an Emotional Milestone
Receiving the first undetectable viral-load result can bring relief, pride, disbelief, or all three at once. The result confirms that treatment is controlling the virus, but it may also take time for someone to trust the science of U=U. Clinicians often reinforce that sustained viral suppression prevents sexual transmission while emphasizing the importance of ongoing treatment and laboratory monitoring.
Switching Regimens Is Not Necessarily Treatment Failure
A person may switch HIV medications because of side effects, drug interactions, pregnancy plans, kidney concerns, simplification, or a preference for injections. A successful switch is routine medical optimization, not evidence that the patient has “failed.”
For example, someone whose virus has remained suppressed for years may be eligible for Cabenuva and appreciate removing daily pills from their routine. Another person may try injections and decide that scheduled clinic visits and temporary soreness are less convenient than a tablet. Neither preference is more responsible or modern. The winning option is the one that fits safely into the person’s life.
Prevention Medication Also Requires a Plan
PrEP users face similar practical choices. One person may prefer an inexpensive generic daily tablet. Another may choose Apretude because remembering pills is difficult. Someone seeking the longest interval between doses may discuss Yeztugo with a clinician. The freedom offered by long-acting medication comes with a tradeoff: appointments must be scheduled and kept, and follow-up HIV testing remains essential.
These experiences share one theme. HIV medication works best when medical science and everyday life cooperate. Treatment is not merely swallowing a chemical or receiving an injection. It is an ongoing partnership involving testing, honest conversations, access to medication, manageable routines, and adjustments when circumstances change.
Conclusion
The modern HIV medications list includes numerous drug classes, convenient combination tablets, specialized medicines for resistant virus, and long-acting injections. ART can reduce HIV to an undetectable level, protect immune health, and prevent sexual transmission. PrEP can prevent HIV before exposure, while PEP provides emergency protection after a possible exposure.
No single regimen is ideal for everyone. Resistance results, hepatitis B status, kidney and liver health, pregnancy, other medications, cost, and daily routines all influence the decision. The safest approach is to work with an experienced clinician, take medication exactly as prescribed, complete recommended laboratory monitoring, and discuss problems early rather than quietly abandoning treatment.
Note: Medication approvals, brand availability, and treatment guidelines can change. This article reflects U.S. information available through July 2026 and is intended for general education. It does not replace HIV testing, emergency PEP evaluation, or individualized medical advice.
